University of Copenhagen
New research out of Denmark is showing promise for treating neuropathic pain. According to the team of researchers, they have been focusing on targeting hyper-sensitive nerves that contribute to chronic pain onset. They’ve done this by developing an experimental compound – a peptide called Tat-P4-(C5)2 – that has proved effective in treating similar pain in mice.
“We have developed a new way to treat chronic pain. It is a targeted treatment. That is, it does not affect the general neuronal signaling, but only affects the nerve changes that are caused by the disease,” says Kenneth Lindegaard Madsen, PhD, Associate Professor at the University of Copenhagen.
“We have been working on this for more than ten years. We have taken the process all the way from understanding the biology, inventing and designing the compound to describing how it works in animals, affects their behavior and removes the pain,” said Madsen.
How The Peptide Works
The image on this blog shows the Tat-P4-(C5)2 compound after it is injected into the spinal cord. The compound (purple) begins by penetrating the nerve cells of the spinal cord (yellow), but not the surrounding cells (cell nuclei can be seen in blue). The compound works by blocking neuropathic pain signals like the kind that are seen in patients dealing with diabetic neuropathy, CRPS or phantom limb pain. The team has been pleased with how successful the treatment has been in mice.
“The compound works very efficiently, and we do not see any side effects. We can administer this peptide and obtain complete pain relief in the mouse model we have used, without the lethargic effect that characterizes existing pain-relieving drugs,” said Madsen. “Now, our next step is to work towards testing the treatment on people. The goal, for us, is to develop a drug, therefore the plan is to establish a biotech company as soon as possible so we can focus on this.”
Aside from simply working to block pain signals from being interpreted by the brain, researchers believe a peptide-focused treatment may become the norm for a variety of pain conditions in the future because it can perform the same task as painkillers without the risk of addiction or dependence. Our bodies naturally build up a tolerance to traditional painkillers, and as dosage increases so too does the risk of dependence and overdose. But with peptide intervention, we can block pain signals without the need for potentially dangerous painkillers.
It’s far from a miracle cure, and even if it’s proven successful in a human trial it should be paired with other healthy habits like regular exercise and dietary improvements, but it certainly gives us hope for the future of pain care. We’ll keep our eyes on this research as it moves to the next stage of trial. In the meantime, if you need help with a chronic pain issue, let us help you. Contact Dr. Cohn’s office today for more information.